PET/MR User's Meeting: Technical challenges Feb 05, 2020 10:30 AM - 03:00 PM — Henry Wellcome Auditorium, 183 Euston Road, London
Launch event for Aberdeen Hub of One HealthTech Feb 13, 2020 06:00 PM - 09:00 PM — ONE Tech Hub, Schoolhill, Aberdeen
Scottish Ophthalmic Imaging Society meeting Feb 14, 2020 09:30 AM - 05:00 PM — Royal Society of Edinburgh, 22-26 George Street, Edinburgh
Scottish+ Radiotherapy Physics Meeting 2020 Feb 21, 2020 09:30 AM - 05:00 PM — Scottish Health Service Centre , Western General Hospital, Edinburgh
2nd Scottish Ultrasound Annual Scientific Meeting Feb 28, 2020 10:00 AM - 05:00 PM — Collins Building, University of Strathclyde

eLearning

SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.


Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy

Author(s): A. Sorensen, R. J. Mairs, L. Braidwood, C. Joyce, J. Conner, S. Pimlott, M. Brown, M. Boyd

Abstract:
Oncolytic herpes viruses show promise for cancer treatment. However, it is unlikely that they will fulfill their therapeutic potential when used as monotherapies. An alternative strategy is to use these viruses not only as oncolytic agents but also as a delivery mechanism of therapeutic transgenes to enhance tumor cell killing. The herpes simplex virus 1 deletion mutant HSV1716 is a conditionally replicating oncolytic virus that selectively replicates in and lyses dividing tumor cells. It has a proven safety profile in clinical trials and has demonstrated efficacy as a gene-delivery vehicle. To enhance its therapeutic potential, we have engineered HSV1716 to convey the noradrenaline transporter (NAT) gene (HSV1716/NAT), whose expression endows infected cells with the capacity to accumulate the noradrenaline analog metaiodobenzylguanidine (MIBG). Thus, the NAT gene-infected cells are susceptible to targeted radiotherapy using radiolabeled (131)I-MIBG, a strategy that has already shown promise for combined targeted radiotherapy-gene therapy in cancer cells after plasmid-mediated transfection. METHODS: We used HSV1716/NAT as a dual cell lysis-gene delivery vehicle for targeting the NAT transgene to human tumor xenografts in vivo. RESULTS: In tumor xenografts that did not express NAT, intratumoral or intravenous injection of HSV1716/NAT induced the capacity for active uptake of (131)I-MIBG. Administration of HSV1716/NAT and (131)I-MIBG resulted in decreased tumor growth and enhanced survival relative to injection of either agent alone. Efficacy was dependent on the scheduling of delivery of the 2 agents. CONCLUSION: These findings support a role for combination radiotherapy-gene therapy for cancer using HSV1716 expressing the NAT transgene and targeted radionuclide therapy.

Full version: Available here

Click the link to go to an external website with the full version of the paper


ISBN: 1535-5667 (Electronic) 0161-5505 (Linking)
Publication Year: 2012
Periodical: J Nucl Med
Periodical Number: 4
Volume: 53
Pages: 647-54
Author Address: Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.